| Literature DB >> 31528753 |
Assia Belhassan1,2, Hanane Zaki2,3, Mohamed Benlyas3, Tahar Lakhlifi1, Mohammed Bouachrine1,2.
Abstract
In this study, we have selected a series of a new family of molecules bearing Triazolo-benzodiazepines, an eleven membered heterocyclic ring has been studied for antidepression activity. Docking studies suggested that all the eleven ligands interacted well within active site of Drosophila melanogaster dopamine transporter (dDAT) (PDB ID: 4M48). Most ligands formed H-bond with amino acid Phe43, Asp46, Asp475, Tyr123, Ser421 and/or Gln316 and also exhibited Pi and Pi-Pi interactions with amino acid residues Tyr124, Phe319, Phe43, Phe325, Ala479 and Val120. In silico ADME evaluations of compounds showed more than 96% intestinal absorption for all compounds. During in vitro Toxicity properties prediction, the Triazolo-benzodiazepines derivatives: M1, M2, M3 and M11 showed less toxicity than the other studied molecules against algae, for daphnia the molecules M1, M2, M3, M8, M10 and M11 showed less toxicity than the reference molecule (Nortriptyline).Entities:
Keywords: ADMET properties; Antidepressant activity; Biochemistry; Bioinformatics; Molecular docking; Nortriptyline; Pharmaceutical chemistry; Theoretical chemistry; Triazolo-benzodiazepine
Year: 2019 PMID: 31528753 PMCID: PMC6739292 DOI: 10.1016/j.heliyon.2019.e02446
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Fig. 1Chemical structures of studied compounds.
Chemical structures of the 11 selected Triazolo-benzodiazepines derivatives.
| N° | R | R1 | R2 | R3 |
|---|---|---|---|---|
| 1 | Cyclohexyl | O–CH3 | H | H |
| 2 | Cyclohexyl | O–CH3 | O–CH3 | H |
| 3 | Cyclohexyl | Cl | H | H |
| 4 | CH3 | H | H | |
| 5 | H | H | CH3 | |
| 6 | O–CH3 | H | H | |
| 7 | O–CH3 | O–CH3 | H | |
| 8 | Cl | H | H | |
| 9 | H | H | F | |
| 10 | Cyclohexyl | F | H | H |
| 11 | 1,1,3,3-tetramethyl-butyl | F | H | H |
Comparison of Autodock score (kcal/mol) of the 9 best poses obtained by docking of 11 selected Triazolo-benzodiazepines derivatives and the re-docking of reference molecule (Nortriptyline) with dDAT.
| Ligands | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
|---|---|---|---|---|---|---|---|---|---|
| Ref: Nortriptyline | -10.0 | -9.3 | -9.2 | -9.0 | -8.8 | -8.7 | -8.7 | -8.5 | -8.0 |
| M1 | -10.0 | -9.8 | -9.2 | -9.1 | -9.0 | -8.9 | -8.8 | -8.7 | -8.7 |
| M2 | -9.9 | -9.5 | -9.4 | -9.2 | -9.1 | -8.9 | -8.9 | -8.8 | -8.7 |
| M3 | -10.6 | -10.0 | -10.0 | -9.9 | -9.8 | -9.6 | -9.5 | -9.4 | -9.4 |
| M4 | -10.5 | -9.4 | -9.3 | -9.3 | -9.3 | -9.2 | -9.2 | -9.1 | -8.8 |
| M5 | -10.4 | -9.3 | -9.3 | -9.3 | -9.1 | -8.7 | -8.7 | -8.7 | -8.6 |
| M6 | -9.6 | -9.2 | -9.1 | -9.1 | -9.0 | -9.0 | -8.9 | -8.9 | -8.7 |
| M7 | -10.0 | -9.9 | -9.5 | -9.5 | -9.4 | -9.2 | -9.0 | -9.0 | -8.9 |
| M8 | -10.4 | -9.8 | -9.5 | -9.4 | -9.4 | -9.3 | -9.3 | -9.2 | -8.9 |
| M9 | -10.3 | -9.4 | -9.4 | -9.3 | -9.3 | -9.1 | -9.0 | -8.9 | -8.8 |
| M10 | -12.3 | -10.6 | -10.5 | -10.3 | -10.0 | -10.0 | -9.8 | -9.6 | -9.5 |
| M11 | -10.1 | -10.1 | -9.9 | -9.5 | -9.3 | -9.1 | -8.8 | -8.8 | -8.7 |
Fig. 2Types of interactions between the dDAT (PDB code: 4M48) and Nortriptyline.
Fig. 3Types of interactions between the dDAT (PDB code: 4M48) and the 11 selected Triazolo-benzodiazepines derivatives.
Comparison of interactions formed by docking of 11 selected Triazolo-benzodiazepines derivatives and the re-docking of reference molecule (Nortriptyline) with dDAT.
| Type of interactions | Residues | Molecules | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ref: Nortriptyline | M1 | M2 | M3 | M4 | M5 | M6 | M7 | M8 | M9 | M10 | M11 | |||
| Hydrogen Bonds | Conventional H-Bond | PHE43 | X | X | ||||||||||
| GLN316 | X | |||||||||||||
| ASP46 | X | X | X | |||||||||||
| TYR123 | X | X | X | |||||||||||
| SER421 | X | |||||||||||||
| ASP475 | X | |||||||||||||
| Carbon -H-Bond | SER421 | X | X | X | X | |||||||||
| ASP46 | X | X | X | |||||||||||
| PHE319 | X | X | ||||||||||||
| ALA479 | X | |||||||||||||
| SER320 | X | |||||||||||||
| ASP475 | X | |||||||||||||
| TYR123 | X | |||||||||||||
| ALA44 | X | |||||||||||||
| SER124 | X | |||||||||||||
| Pi-Donor-H-Bond | PHE43 | X | ||||||||||||
| Hydrophobic interactions | Pi-Pi | TYR124 | X | X | X | X | X | X | X | X | ||||
| PHE319 | X | X | X | X | X | |||||||||
| PHE43 | X | X | ||||||||||||
| PHE325 | X | |||||||||||||
| Alkyl | VAL120 | X | X | X | X | X | ||||||||
| ALA479 | X | |||||||||||||
| ILE483 | X | |||||||||||||
| ILE127 | X | |||||||||||||
| ARG52 | X | X | ||||||||||||
| ALA44 | X | X | ||||||||||||
| ALA48 | X | |||||||||||||
| TYR124 | X | |||||||||||||
| Pi-Alkyl | ALA479 | X | X | X | X | |||||||||
| PHE319 | X | X | X | |||||||||||
| PHE325 | X | |||||||||||||
| TRP51 | X | X | ||||||||||||
| TYR123 | X | |||||||||||||
| TYR124 | X | X | X | |||||||||||
| PHE471 | X | |||||||||||||
| VAL120 | X | |||||||||||||
| Pi-Sigma | VAL120 | X | X | X | X | X | X | X | ||||||
| PHE43 | X | X | ||||||||||||
Predicted ADME properties of the 11 studied compounds in comparison with the reference drug.
| Ref | M1 | M2 | M3 | M4 | M5 | M6 | M7 | M8 | M9 | M10 | M11 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BBB | 13.406 | 0.318 | 0.320 | 0.340 | 0.122 | 0.159 | 0.245 | 0.197 | 0.277 | 0.180 | 0.331 | 0.246 |
| BS | 66.488 | 93.970 | 52.011 | 59.350 | 247.204 | 77.602 | 326.688 | 181.526 | 206.459 | 368.859 | 189.694 | 157.659 |
| CYP_2C19_inhibition | Inhibitor | Non | Non | Non | Non | Non | Non | Non | Non | Non | Non | Non |
| CYP_2C9_inhibition | Non | Non | Non | Non | Non | Non | Non | Non | Non | Non | Non | Non |
| CYP_2D6_inhibition | Inhibitor | Non | Non | Non | Non | Non | Non | Non | Non | Non | Non | Non |
| CYP_2D6_substrate | Substrate | Non | Non | Non | Non | Non | Non | Non | Non | Non | Non | Non |
| CYP_3A4_inhibition | Non | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor | Inhibitor |
| CYP_3A4_substrate | Non | Weakly | Substrate | Weakly | Substrate | Substrate | Substrate | Substrate | Substrate | Substrate | Weakly | Substrate |
| HIA | 100 | 96.828 | 97.356 | 96.548 | 96.466 | 96.466 | 97.004 | 97.525 | 96.457 | 96.506 | 96.438 | 96.440 |
| MDCK | 96.879 | 1.121 | 0.143 | 3.675 | 24.933 | 112.593 | 6.772 | 1.476 | 9.663 | 27.802 | 2.223 | 0.043 |
| Pgp_I | Inhibitor | Non | Inhibitor | Inhibitor | Non | Non | Inhibitor | Inhibitor | Inhibitor | Non | Non | Inhibitor |
| PPB | 100 | 90.524 | 89.190 | 91.919 | 88.306 | 87.741 | 83.385 | 80.719 | 87.854 | 88.330 | 89.897 | 89.716 |
| PWS | 2.941 | 2.472 | 1.721 | 0.520 | 9.662 | 18.801 | 22.013 | 15.382 | 4.624 | 21.762 | 1.755 | 0.514 |
| SKlogD_value | 3.500 | 3.554 | 3.5489 | 4.269 | 3.407 | 3.3850 | 2.876 | 2.872 | 3.592 | 3.046 | 3.735 | 4.600 |
| SKlogP_value | 4.844 | 3.554 | 3.5489 | 4.269 | 3.407 | 3.3850 | 2.876 | 2.872 | 3.592 | 3.046 | 3.735 | 4.600 |
| SKlogS_buffer | -3.621 | -3.676 | -3.961 | -3.880 | -3.213 | -3.716 | -3.109 | -3.394 | -3.312 | -3.043 | -3.359 | -3.468 |
| SKlogS_pure | -4.975 | -5.256 | -5.441 | -5.938 | -4.621 | -4.332 | -4.280 | -4.466 | -4.962 | -4.272 | -5.393 | -5.955 |
BBB = in vivo blood-brain barrier penetration (C.brain/C.blood), BS = Buffer Solubility (mg/l), CYP2C19 = cytochrome P4502C19, CYP2C9 = cytochrome P4502C9, CYP3A4 = cytochrome P4503A4, CYP2D6 = cytochrome CYP2D6, PgP I = P-glycoprotein inhibition, PPB = Plasma Protein Binding %, PWS = Pure Water Solubility (mg/l), HIA = Human intestinal absorption %, MDCK = in vitro MDCKcellpermeability (Mandin Darby Canine Kidney (nm/sec)).
Toxicity predicted of the 11 studied compounds in comparison with the reference drug.
| ID | Ref | M1 | M2 | M3 | M4 | M5 | M6 | M7 | M8 | M9 | M10 | M11 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| algae_at | 0.008 | 0.019 | 0.013 | 0.011 | 0.053 | 0.064 | 0.055 | 0.040 | 0.037 | 0.076 | 0.025 | 0.011 | |
| Ames_test | Mutagen | Mutagen | Non-mutagen | Mutagen | Mutagen | Mutagen | Mutagen | Mutagen | Mutagen | Mutagen | Mutagen | Mutagen | |
| Carcino_Mouse | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |
| Carcino_Rat | Positive | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |
| daphnia_at | 0.030 | 0.024 | 0.022 | 0.009 | 0.0434 | 0.044 | 0.078 | 0.070 | 0.029 | 0.059 | 0.020 | 0.012 | |
| hERG_inhibition | Medium_risk | Medium_risk | Medium_risk | Medium_risk | Medium_risk | Medium_risk | Medium_risk | Medium_risk | Medium_risk | Medium_risk | Medium_risk | Medium_risk | |
| TA100_10RLI | Negative | Negative | Negative | Negative | Positive | Positive | Positive | Positive | Positive | Positive | Negative | Negative | |
| TA100_NA | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |
| TA1535_10RLI | Positive | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |
| TA1535_NA | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | |